Combined antenatal vitamin K and phenobarbital therapy for preventing intracranial hemorrhage in newborns less than 34 weeks' gestation

James A. Thorp, Denise Ferrette-Smith, Laura A. Gaston, Joy Johnson, John D. Yeast, Bruce Meyer

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objective: To determine whether maternal antenatal therapy with vitamin K and phenobarbital prevents intracranial hemorrhage in premature newborns. Methods: Women at high risk for spontaneous or indicated premature delivery before 34 weeks' gestation were randomly assigned to receive either placebo or vitamin K and phenobarbital. All patients received betamethasone and antibiotics and were managed uniformly by a single perinatal group in one hospital. All newborns were managed uniformly in the same nursery by one neonatal group. Two independent interpretations of neonatal head ultrasound examinations were obtained. Results: The duration of gestation at study entry and at delivery were similar in the placebo (181 mothers) and treatment (191) groups. With the hospital radiology group (the primary interpreter), the incidence rates of severe intracranial hemorrhage (8 versus 7%) and mild intracranial hemorrhage (38 versus 32%) were similar for both groups. With the secondary interpreter (a single pediatric radiologist), the incidence rates of severe intracranial hemorrhage (9 versus 7%) and mild intracranial hemorrhage (27 versus 26%) were also similar. Neonatal mortality was equivalent in both the placebo and treatment groups (8 versus 10%). Conclusion: Combined antenatal therapy with vitamin K and phenobarbital does not reduce the frequency or severity of intracranial hemorrhage in premature newborns.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalObstetrics and Gynecology
Volume86
Issue number1
DOIs
StatePublished - 1995

Fingerprint

Vitamin K
Intracranial Hemorrhages
Phenobarbital
Newborn Infant
Pregnancy
Placebos
Therapeutics
Mothers
Betamethasone
Nurseries
Incidence
Infant Mortality
Radiology
Head
Pediatrics
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Combined antenatal vitamin K and phenobarbital therapy for preventing intracranial hemorrhage in newborns less than 34 weeks' gestation. / Thorp, James A.; Ferrette-Smith, Denise; Gaston, Laura A.; Johnson, Joy; Yeast, John D.; Meyer, Bruce.

In: Obstetrics and Gynecology, Vol. 86, No. 1, 1995, p. 1-8.

Research output: Contribution to journalArticle

Thorp, James A. ; Ferrette-Smith, Denise ; Gaston, Laura A. ; Johnson, Joy ; Yeast, John D. ; Meyer, Bruce. / Combined antenatal vitamin K and phenobarbital therapy for preventing intracranial hemorrhage in newborns less than 34 weeks' gestation. In: Obstetrics and Gynecology. 1995 ; Vol. 86, No. 1. pp. 1-8.
@article{a71bc9edd9d54cd286196bf08c3c0b31,
title = "Combined antenatal vitamin K and phenobarbital therapy for preventing intracranial hemorrhage in newborns less than 34 weeks' gestation",
abstract = "Objective: To determine whether maternal antenatal therapy with vitamin K and phenobarbital prevents intracranial hemorrhage in premature newborns. Methods: Women at high risk for spontaneous or indicated premature delivery before 34 weeks' gestation were randomly assigned to receive either placebo or vitamin K and phenobarbital. All patients received betamethasone and antibiotics and were managed uniformly by a single perinatal group in one hospital. All newborns were managed uniformly in the same nursery by one neonatal group. Two independent interpretations of neonatal head ultrasound examinations were obtained. Results: The duration of gestation at study entry and at delivery were similar in the placebo (181 mothers) and treatment (191) groups. With the hospital radiology group (the primary interpreter), the incidence rates of severe intracranial hemorrhage (8 versus 7{\%}) and mild intracranial hemorrhage (38 versus 32{\%}) were similar for both groups. With the secondary interpreter (a single pediatric radiologist), the incidence rates of severe intracranial hemorrhage (9 versus 7{\%}) and mild intracranial hemorrhage (27 versus 26{\%}) were also similar. Neonatal mortality was equivalent in both the placebo and treatment groups (8 versus 10{\%}). Conclusion: Combined antenatal therapy with vitamin K and phenobarbital does not reduce the frequency or severity of intracranial hemorrhage in premature newborns.",
author = "Thorp, {James A.} and Denise Ferrette-Smith and Gaston, {Laura A.} and Joy Johnson and Yeast, {John D.} and Bruce Meyer",
year = "1995",
doi = "10.1016/0029-7844(95)00091-5",
language = "English (US)",
volume = "86",
pages = "1--8",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Combined antenatal vitamin K and phenobarbital therapy for preventing intracranial hemorrhage in newborns less than 34 weeks' gestation

AU - Thorp, James A.

AU - Ferrette-Smith, Denise

AU - Gaston, Laura A.

AU - Johnson, Joy

AU - Yeast, John D.

AU - Meyer, Bruce

PY - 1995

Y1 - 1995

N2 - Objective: To determine whether maternal antenatal therapy with vitamin K and phenobarbital prevents intracranial hemorrhage in premature newborns. Methods: Women at high risk for spontaneous or indicated premature delivery before 34 weeks' gestation were randomly assigned to receive either placebo or vitamin K and phenobarbital. All patients received betamethasone and antibiotics and were managed uniformly by a single perinatal group in one hospital. All newborns were managed uniformly in the same nursery by one neonatal group. Two independent interpretations of neonatal head ultrasound examinations were obtained. Results: The duration of gestation at study entry and at delivery were similar in the placebo (181 mothers) and treatment (191) groups. With the hospital radiology group (the primary interpreter), the incidence rates of severe intracranial hemorrhage (8 versus 7%) and mild intracranial hemorrhage (38 versus 32%) were similar for both groups. With the secondary interpreter (a single pediatric radiologist), the incidence rates of severe intracranial hemorrhage (9 versus 7%) and mild intracranial hemorrhage (27 versus 26%) were also similar. Neonatal mortality was equivalent in both the placebo and treatment groups (8 versus 10%). Conclusion: Combined antenatal therapy with vitamin K and phenobarbital does not reduce the frequency or severity of intracranial hemorrhage in premature newborns.

AB - Objective: To determine whether maternal antenatal therapy with vitamin K and phenobarbital prevents intracranial hemorrhage in premature newborns. Methods: Women at high risk for spontaneous or indicated premature delivery before 34 weeks' gestation were randomly assigned to receive either placebo or vitamin K and phenobarbital. All patients received betamethasone and antibiotics and were managed uniformly by a single perinatal group in one hospital. All newborns were managed uniformly in the same nursery by one neonatal group. Two independent interpretations of neonatal head ultrasound examinations were obtained. Results: The duration of gestation at study entry and at delivery were similar in the placebo (181 mothers) and treatment (191) groups. With the hospital radiology group (the primary interpreter), the incidence rates of severe intracranial hemorrhage (8 versus 7%) and mild intracranial hemorrhage (38 versus 32%) were similar for both groups. With the secondary interpreter (a single pediatric radiologist), the incidence rates of severe intracranial hemorrhage (9 versus 7%) and mild intracranial hemorrhage (27 versus 26%) were also similar. Neonatal mortality was equivalent in both the placebo and treatment groups (8 versus 10%). Conclusion: Combined antenatal therapy with vitamin K and phenobarbital does not reduce the frequency or severity of intracranial hemorrhage in premature newborns.

UR - http://www.scopus.com/inward/record.url?scp=0029014268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029014268&partnerID=8YFLogxK

U2 - 10.1016/0029-7844(95)00091-5

DO - 10.1016/0029-7844(95)00091-5

M3 - Article

C2 - 7784000

AN - SCOPUS:0029014268

VL - 86

SP - 1

EP - 8

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 1

ER -